We recently compiled a list of the 10 Dogs of the Dow Dividend Stocks to Invest in. In this article, we are going to take a ...

We recently published a list of 10 Cheap NYSE Stocks To Invest In Now. In this article, we are going to take a look at where ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines. Click here to check out my ...

On Thursday, Merck & Co Inc (NYSE:MRK) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection. The trials ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $99.52 which represents a slight increase of $1.18 or 1.20% from the prior close of $98.34. The stock opened at $98.56 and touched a ...

An FDA approval of Merck’s drug clesrovimab by June would give physicians another option for protecting newborns from ...

However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...

Shares of Merck & Co (MRK) continue to trend lower. If they reach the $95.00 level, there is a good chance they find support ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other dividend stocks. Dividend-focused investors are often drawn to stocks with high yields ...